To cite this paper use one of the standards below:
Introduction: Natalizumab (NTZ) is a humanized monoclonal antibody indicated for people with multiple sclerosis (pwMS) with poor response to first-line treatment or naive-patients with highly active disease. NTZ exposure in JC-virus (JCV)–seropositive patients increase the risk of developing a severe opportunistic infection called progressive multifocal leukoencephalopathy (PML). By searching for an exit strategy for NTZ cessation we can undermine PML risk in such patients.
Objectives: To evaluate NTZ exit strategies in a northeast Brazilian MS center.
Methods: Observational data from patients under NTZ treatment between July 2010 and April 2024.
Results: 21 patients were enrolled, with median follow-up in years of 7 (IQR 5-11). 86% were female, with median age of 39 years old (IQR 32-44) and median disease duration of 15 years (IQR 7-23). The median EDSS during NTZ follow-up was 2 (IQR 1,5-5) and average infusion of 29 (SD 20). Although 90% of patients had disease activity 2 years prior NTZ, only one had relapse during treatment. Eighteen patients interrupted NTZ due JCV-index higher than 1,5 and three between 0,9 and 1,5. From 21 patients undergoing cessation, one switched to Fingolimod, one to Ofatumumab, five to Rituximab and fourteen to Ocrelizumab. There were no relapses after interruption, 2 patients had signs of radiologic activity and median EDSS remained 2 (IQR 1,5-5). After cessation, 5 patients under Ocrelizumab had infusions delays due availability issues and the one under Fingolimod switched to Rituximab due side effects.
Conclusion: The risk of PML remains a major concern and there is a lack of solid strategies for patients under NTZ over 24 months and positive JCV. Ocrelizumab has a high patient-per-year cost, and it is not currently available in public health care, which may increase the risk of disease activity due erratic use. Rituximab presents as an available option in limited resource scenarios.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper